Drugs / Immunoglobulins
Immunoglobulins
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01828294 | Oct 2011 → Dec 2017 | AChR+ myasthenia gravis | St. Louis University | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06373211 | Jan 2025 → Jun 2028 expected | paraneoplastic sensory ganglionopathy | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT06159283 | Mar 2024 → Jun 2025 | COVID-19 | Jaehoon Ko | Unknown | No outcome recorded |
| Phase 2 | NCT03289403 | Mar 2018 → Sep 2023 | autoimmune thyroid disease, infertility disorder | Aljazeera Hospital | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04222023 | Aug 2022 → Aug 2025 | — | University Hospital, Strasbourg, France | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03534479 | Apr 2010 → Apr 2013 | common variable immunodeficiency | Federico II University | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-03-26 | CSL Behring | Japan’s Ministry of Health, Labour and Welfare Approves CSL Behring Immunoglobulins to Treat Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) csl.com ↗ |
| 2012-10-04 | CSL Behring | New Model Compares Economic Value of Subcutaneous Immunoglobulin Therapy with Intravenous Immunoglobulin csl.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | immunoglobulins | “3. Immunoglobulins will be used in cases not responding to treatment.” NCT03289403 ↗ |
| Known as | CLAYRIG | “Immunoglobulins IV (CLAYRIG)” NCT06373211 ↗ |
| Known as | IGSC | “subcutaneous immunoglobulin (SCIG or IGSC) as a maintenance therapy” NCT01828294 ↗ |
| Known as | intravenous immunoglobulin | “intravenous immunoglobulin (IVIG) replacement therapy” NCT06159283 ↗ |
| Known as | IVIG | “intravenous immunoglobulin (IVIG) replacement therapy” NCT06159283 ↗1“Intravenous immunoglobulins (IVIG)” NCT04222023 ↗ |
| Known as | Polyclonal IgG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03534479 ↗ |
| Known as | SCIG | “subcutaneous immunoglobulin (SCIG or IGSC) as a maintenance therapy” NCT01828294 ↗ |
| Modality | Protein / enzyme biologic | “which is a plasma protein” NCT01828294 ↗ |
| Route | Subcutaneous | “Immunoglobulins used subcutaneously” NCT01828294 ↗ |